Xentuzumab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameXentuzumab
Drug Alias NameBI-836845
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInsulin-like growth factor I inhibitorsInsulin-like growth factor II inhibitors
TargetsInsulin-like growth factor IIInsulin-like growth factor I
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgUniversity Of Oxford
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A